Richmond Va-based INSMED, a US-based follow-on biologics manufacturer, posted a press release on its website entitled: “Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company” that reports on the results from a Phase I clinical trial that demonstrated that it lead product INS-19 was bioequivalent to Amgen’s Neupogen(R) (recombinant G-CSF) in stimulating human white blood cell production.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments